首页> 外文会议>Conference of the National Institutes of Health >Tumorigenicity Assessmentsof PER.C6~R Cellsand of an Ad5-Vectored HIV-1Vaccine Producedon this Continuous Cell Line
【24h】

Tumorigenicity Assessmentsof PER.C6~R Cellsand of an Ad5-Vectored HIV-1Vaccine Producedon this Continuous Cell Line

机译:致瘤性评估Per.C6〜R Celland和AD5矢量HIV-1VACCONE的产生该连续细胞系

获取原文

摘要

PER.C6~R, a cell line derived from human embryonic retinal cells transformed with the Adenovirus Type 5 (Ad5) ElAand E1B genes, is used to produce E1 -deleted Ad5 vectors such as the MRKAd5 HIV-1 gag vaccine. While whole, live PER.C6~R cells are capable of growing as tumours when transplanted subcutaneously into immunodeficient nude mice at a high dosage, the process for vaccine production includes filtration steps and other methods which effectively preclude contamination by intact viable substratecells. However, because of the neoplastic nature of this cell line, we carried out a series of investigations to assess the tumorigenic risk posed by residuals from the cell substrate in a vaccine. To address concerns about transmission of oncogenic DNA,we demonstrated that purified PER.C6~R cellular DNA does not induce tumours in newborn hamsters or nude mice. To address concerns about other potential residuals, including hypothetical adventitious tumour viruses, we demonstrated that a PER.C6'5' celllysate and a MRKAd5 HIV-1 gag vaccine produced on PER.C6~E cells do not induce tumours in newborn hamsters or newborn rats. These results, in conjunction with the wide panel of viral safety tests performed on these cells, support the safety of the PER.C6~R as a cell substrate for vaccine production.
机译:Per.C6〜R,衍生自与腺病毒型5(AD5)ElaAnd E1b基因转化的人胚胎视网膜细胞的细胞系,用于生产E1 -DeletedAd5载体,例如MRKAD5 HIV-1 GAG疫苗。虽然全部,活性为每种情况,但在高剂量下皮进入免疫缺陷裸鼠时的肿瘤,疫苗生产方法包括过滤步骤和其他方法,其有效地通过完整的活性外包集抑制污染。然而,由于这种细胞系的肿瘤性质,我们进行了一系列的研究,以评估残留在疫苗中的细胞基质的残留瘤风险。为了满足关于致癌DNA的传播的担忧,我们证明了纯化的per.C6〜R细胞DNA不会诱导新生儿仓鼠或裸鼠中的肿瘤。为了满足对其他潜在残留物的担忧,包括假设不偶诱变肿瘤病毒,我们证明了每种C6'5'蜂窝和MRKAD5 MRKAD5 HIV-1 GAG疫苗在新生儿仓鼠或新生儿中不会诱导肿瘤老鼠。这些结果与对这些细胞进行的宽面板的病毒安全性试验结合,支持PER.C6〜R作为疫苗生产的细胞基底的安全性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号